TIKRF Tikcro Technologies Ltd.

Tikcro Technologies Ltd. operates as a biopharmaceutical company. It pursues an early stage biotechnology project generating new antibodies for cancer treatment addressing immune modulation. This project is based on technology from the Weizmann Institute of Science in Israel. It promotes a new approach for the generation of antibodies which are expected to have selectivity and blocking capabilities and, as a result, are expected to effectively modulate the immune system. Tikcro Technologies was founded on December 14, 1999 and is headquartered in Ness Ziona, Israel.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.30    Pink
As of 01/24/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Financials
Industry:  Shell Companies
Index country:  Israel
Country of incorporation:  
IPO date:  06/26/2000
Outstanding shares:  11,370,904
Average volume:  444
Market cap:   $625,400
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.16
PS ratio:   0.00
Return on equity:   -12.76%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy